Gene Signal enters Phase III clinical tests for the prevention of Corneal Graft Rejection
Lausanne (ots) - - Gene Signal International, a biotech company registered in Switzerland, will move its headquarter to the EPFL, in Lausanne, - Gene Signal is addressing various issues related to neovascularisation, - Gene Signal is working on a portfolio of ophthalmologic indications, with one now in Phase III trials - Gene Signal ...
mehr